| Mary Jo Villar, DO | |
|
7600 W 20th Ave, Ste 103-104, Hialeah, FL 33016-1821 | |
| (305) 231-3150 | |
| (305) 231-5020 |
| Full Name | Mary Jo Villar |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 7600 W 20th Ave, Hialeah, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003804287 | NPI | - | NPPES |
| 258647900 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 0S 7470 (Florida) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mary Jo Villar, DO 7600 W 20th Ave, Ste 103-104, Hialeah, FL 33016-1821 Ph: (305) 231-3150 | Mary Jo Villar, DO 7600 W 20th Ave, Ste 103-104, Hialeah, FL 33016-1821 Ph: (305) 231-3150 |
News Archive
More than 100 doctors and healthcare professionals will be in Washington, DC, to give the President, legislators, and the American people a "Second Opinion" on how to fix our healthcare system. Representing the more than 10,000 members of the Coalition to Protect Patients' Rights, these healthcare professionals from across the country will give legislators their frontline perspective of what needs to be fixed in healthcare – and what doesn't.
Five Boulder County health care organizations have signed agreements to share patient data through the Colorado Regional Health Information Organization's Health Information Exchange, CORHIO officials announced today.
Bowel (colorectal) cancer is the third most commonly occurring cancer in men and the second most commonly occurring cancer in women worldwide. The global burden is expected to increase by 60 per cent to more than 2.2 million new cases and 1.1 million deaths by 2030.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top line results from the pivotal trial of single agent brentuximab vedotin (SGN-35), an antibody drug conjugate (ADC) targeted to CD30. The trial was conducted in 102 relapsed or refractory Hodgkin lymphoma (HL) patients.
"Investigators gave more details about the positive results of the Partners PrEP Study Tuesday at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle," the Center for Global Health Policy's "Science Speaks" blog reports.
› Verified 1 days ago
Onix Cesar Garib Alpizar, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 2140 W 68th St Ste 300, Hialeah, FL 33016 Phone: 305-822-4107 Fax: 305-822-5086 | |
Aaron Rodas, Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1475 W 49th Pl, Hialeah, FL 33012 Phone: 305-558-2500 | |
Francisco J Dieguez Jr., MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 145 E 49th St, Hialeah, FL 33013 Phone: 305-575-1776 Fax: 305-575-1780 | |
Miguel A. Diaz, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 7100 W 20th Ave Ste 205, Hialeah, FL 33016 Phone: 305-817-1344 Fax: 305-817-1355 | |
Reynier Pomares Castillo, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 5961 Nw 173rd Dr, Hialeah, FL 33015 Phone: 305-556-7500 Fax: 305-851-5708 | |
Manuel Suarez, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1435 W 49th Pl, Suite 207, Hialeah, FL 33012 Phone: 305-556-8556 Fax: 305-556-6112 |